Triptolide: A Critical Review on Antiangiogenesis in Cancer and Scope in Therapeutics
Triptolide (TPL) is a traditional Chinese medicine and an active component of a Chinese herb Tripterygium wilfordii F. (Celastraceae). Triptolide has been used to treat a variety of ailments, including rheumatoid arthritis, nephritic syndrome and Lupus erythematosus. It is also a strong antitumor agent. Several angiogenesis assays in numerous research studies have shown that triptolide is an angiogenesis inhibitor. Numerous preclinical studies have shown that TPL inhibits cell proliferation, induces apoptosis and limits tumor metastasis. TPL also has a synergistic action with other treatment methods whereby, it enhances the effects of other antitumor treatments, as studied in various cancer cell lines. This review summarizes the recent developments and discussion of antiangiogenic mechanisms of TPL in cancer, brief outline of its clinical trials and its future in cancer therapeutics.
A. Naila and Y. F. Zhang, "Triptolide: A Critical Review on Antiangiogenesis in Cancer and Scope in Therapeutics", Journal of Biomimetics, Biomaterials and Biomedical Engineering, Vol. 23, pp. 37-46, 2015